We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Eli Lilly and Boehringer Ingelheim received a complete response letter from the FDA for their supplemental NDA for Jardiance (empagliflozin) 2.5mg as an adjunct to insulin for adults with type 1 diabetes. Read More
Ofev was previously approved to treat idiopathic pulmonary fibrosis and to slow the rate of decline in pulmonary function among patients with ILD associated with systemic sclerosis or scleroderma. Read More